CTLA4 and lung cancer: Till date, ipilimumab (IgG1 monoclonal antibody cytotoxic T-lymphocyte associated antigen 4, CTLA-4), pembrolizumab, nivolumab, cemiplimab, durvalumab and atezolizumab are approved for various indications in lung cancers.